Frontiers in endocrinology · 2026
Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Lingling, Ju Yuxin, Zhu Yuanyuan, Xu Jianbo, Lu Dan
Аннотация
BACKGROUND: Polycystic ovary syndrome (PCOS) is often associated with androgen excess, insulin resistance, and low-grade inflammation. While progesterone is standard for regulating menstrual cycles, additional therapies are often needed to address metabolic and inflammatory dysfunctions. Berberine has shown insulin-sensitizing and anti-inflammatory actions that may complement standard hormonal therapy.
OBJECTIVES: This study was designed to evaluate whether adding oral berberine to luteal-phase progesterone improves anthropometric, hormonal, metabolic, and inflammatory indicators in women with PCOS compared with progesterone alone.
METHODS: Women with PCOS who received either berberine plus luteal-phase progesterone or progesterone alone for 3 months were retrospectively analyzed. Clinical records were reviewed for anthropometric, hormonal, metabolic, and inflammatory outcomes, assessed at baseline and after treatment.
RESULTS: The berberine group showed significant within-group reductions in weight, BMI, and WHR; no significant changes occurred in the controls. Crude post-treatment between-group differences in weight, BMI, and WHR were not significant, but became significant for weight and BMI after adjustment. Although the LH and LH/FSH ratio declined in both groups, the adjusted post-treatment values were significantly lower in the berberine group compared to the control group, indicating a superior effect. Total testosterone fell only in the berberine group, yielding significant crude and adjusted between-group differences. Metabolically, fasting insulin, FBS, and HOMA-IR decreased significantly in the berberine group but not in the control group, with crude and adjusted between-group differences remaining significant. Inflammatory markers (CRP, TNF-α, IL-6) declined significantly only in the berberine group. Between-group comparisons were significant in CRP, TNF-α, and IL-6 at 3 months after adjustment.
CONCLUSIONS: These preliminary findings suggest that adjunctive berberine therapy may improve anthropometric, hormonal, metabolic, and inflammatory profiles in women with PCOS. However, well-designed randomized controlled trials are required to confirm these effects and establish definitive clinical recommendations.
OBJECTIVES: This study was designed to evaluate whether adding oral berberine to luteal-phase progesterone improves anthropometric, hormonal, metabolic, and inflammatory indicators in women with PCOS compared with progesterone alone.
METHODS: Women with PCOS who received either berberine plus luteal-phase progesterone or progesterone alone for 3 months were retrospectively analyzed. Clinical records were reviewed for anthropometric, hormonal, metabolic, and inflammatory outcomes, assessed at baseline and after treatment.
RESULTS: The berberine group showed significant within-group reductions in weight, BMI, and WHR; no significant changes occurred in the controls. Crude post-treatment between-group differences in weight, BMI, and WHR were not significant, but became significant for weight and BMI after adjustment. Although the LH and LH/FSH ratio declined in both groups, the adjusted post-treatment values were significantly lower in the berberine group compared to the control group, indicating a superior effect. Total testosterone fell only in the berberine group, yielding significant crude and adjusted between-group differences. Metabolically, fasting insulin, FBS, and HOMA-IR decreased significantly in the berberine group but not in the control group, with crude and adjusted between-group differences remaining significant. Inflammatory markers (CRP, TNF-α, IL-6) declined significantly only in the berberine group. Between-group comparisons were significant in CRP, TNF-α, and IL-6 at 3 months after adjustment.
CONCLUSIONS: These preliminary findings suggest that adjunctive berberine therapy may improve anthropometric, hormonal, metabolic, and inflammatory profiles in women with PCOS. However, well-designed randomized controlled trials are required to confirm these effects and establish definitive clinical recommendations.